Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 6Triple Negative Breast Neoplasms 3Recurrence 3Prostatic Neoplasms 3Urinary Bladder Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Carcinoma, Non-Small-Cell Lung 2Turcot syndrome 1Thyroid Neoplasms 1Tertiary Lymphoid Structures 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Non-Muscle Invasive Bladder Neoplasms 1Multiple Myeloma 1Mucopolysaccharidosis I 1Mesothelioma, Malignant 1Lymphoma, T-Cell, Peripheral 1Liposarcoma 1Inhibition of Autophagy Synergizes Anti-tumor Effect 1Immunoblastic Lymphadenopathy 1Hodgkin Disease 1Genetic Diseases, Inborn 1Gastro-enteropancreatic neuroendocrine tumor 1Esophageal Squamous Cell Carcinoma 1

Interventions

valrubicin 3dodecyl maltoside 3Mitomycin 3Gemcitabine 3durvalumab 2Magnetic Resonance Imaging 2Electrocardiography 2Diphenhydramine 2Cystoscopy 2Biopsy 2Acetaminophen 2toripalimab 1pembrolizumab 1fludarabine phosphate 1fludarabine 1enfortumab vedotin 1cemiplimab 1apaziquone 1aldesleukin 1advexin 1Tomography, X-Ray Computed 1Surveys and Questionnaires 1Standard of Care 1Respiratory Function Tests 1Proflavine 1Prochlorperazine 1Positron-Emission Tomography 1Physical Examination 1Ondansetron 1Oncolytic Virotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carcinoma in Situ × Clinical Trials, Phase II as Topic × Clear all
NCT04752722 2026-04-30

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

enGene, Inc.

Phase 1/2 Recruiting
350 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

Data powered by HemOnc (CC BY 4.0) Colophon âš¡